PT - JOURNAL ARTICLE AU - Martin Direder AU - Tamara Weiss AU - Dragan Copic AU - Vera Vorstandlechner AU - Maria Laggner AU - Caterina Selina Mildner AU - Katharina Klas AU - Daniel Bormann AU - Werner Haslik AU - Christine Radtke AU - Matthias Farlik AU - Lisa Shaw AU - Bahar Golabi AU - Erwin Tschachler AU - Konrad Hötzenecker AU - Hendrik Jan Ankersmit AU - Michael Mildner TI - Schwann cells contribute to keloid formation AID - 10.1101/2021.08.09.21261701 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.09.21261701 4099 - http://medrxiv.org/content/early/2021/08/10/2021.08.09.21261701.short 4100 - http://medrxiv.org/content/early/2021/08/10/2021.08.09.21261701.full AB - Keloids are disfiguring, hypertrophic scars with yet poorly understood pathomechanisms, which could lead to severe functional impairments. Here we analyzed the characteristics of keloidal cells by single cell sequencing and discovered the presence of an abundant population of Schwann cells that persisted in the hypertrophic scar tissue after wound healing. In contrast to normal skin, keloidal Schwann cells possess a repair-like phenotype and high cellular plasticity. Our data support the hypothesis that keloidal Schwann cells contribute to the formation of the extracellular matrix and are able to affect M2 polarization of macrophages. Indeed, we show that macrophages in keloids predominantly display a M2 polarization and produce factors that inhibit Schwann cell differentiation. Our data suggest a contribution of this cross-talk to the continuous expansion of keloids, and that targeting Schwann cells might represent an interesting novel treatment option for keloids.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe present study was financed by the FFG Grant -APOSEC-(852748 and 862068; 2015-2019), the Vienna Business Agency-APOSEC to clinic-(ID 2343727, 2018-2020) and by the Aposcience AG under the direction of group leader HJA. The Sparkling Science Program of the Austrian Federal Ministry of Education, Science and Research (SPA06/055) funded MM. We would like to thank Hans Peter Haselsteiner and the CRISCAR Familienstiftung for their ongoing support of the Medical University/Aposcience AG public private partnership aiming to augment basic and translational clinical research in Austria/Europe. The authors acknowledge the core facilities of the Medical University of Vienna, a member of Vienna Life Science Instruments. We also thank Matthias Wielscher for his support in bioinformatics issues. We thank Barbara Messner and her team for providing the SMA antibody used in this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of resected skin and keloid tissue has been approved by the ethics committee of the Medical University of Vienna (votes 217/2010 and 1190/2020) in accordance with the guidelines of the Council for International Organizations of Medical Sciences (CIOMS).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesScRNASeq data will be available after publication upon request.